Nihon Chouzai
3341.TTSE PRIME
Financials · Standalone
| Fiscal year ended | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 | 2020-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥315.6bn | ¥298.0bn | ¥275.3bn | ¥259.2bn | ¥233.6bn | ¥223.8bn |
| Operating income | ¥5.7bn | ¥7.8bn | ¥7.9bn | ¥5.9bn | ¥5.3bn | — |
| Ordinary income | ¥7.0bn | ¥8.6bn | ¥8.6bn | ¥6.6bn | ¥7.0bn | ¥5.3bn |
| Total assets | ¥157.2bn | ¥155.7bn | ¥148.3bn | ¥140.1bn | ¥145.5bn | ¥144.9bn |
| Net assets / equity | ¥44.3bn | ¥43.8bn | ¥41.5bn | ¥39.2bn | ¥37.7bn | ¥34.9bn |
| EPS (basic) | ¥43.94 | ¥99.76 | ¥105.35 | ¥77.25 | ¥116.69 | ¥155.83 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 15
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 203 figures · EDINET |
| 2023-04-01 → 2024-03-31 | AnnualAmended | 203 figures · EDINET |
| 2022-04-01 → 2023-03-31 | AnnualAmended | 203 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 203 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 203 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2021-04-01 → 2022-03-31 | AnnualAmended | 203 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 203 figures · EDINET |
23 more reports are still being processed.
Segments · FY ended 2025-03
| Segment | External sales | Profit |
|---|---|---|
| Dispensing Pharmacy Business | ¥322.0bn | ¥13.4bn |
| Medical Professional Staffing And Placement Business | ¥11.2bn | ¥937m |
| Pharmaceutical Manufacturing And Sales Business | ¥27.4bn | −¥630m |
| Adjustments & eliminations | — | −¥7.5bn |
| Total | ¥360.5bn | ¥13.8bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.